MLchartDataset catalogue

Leuprolide acetate

Term · Oncology and biomedicine · MLC-T-ONC-004801

  1. A drug used under the brand names Eligard and Lupron Depot to treat prostate cancer and under the brand name Lupron Depot to treat problems with the endometrium (lining of the uterus) and uterine fibroids (noncancerous growths of the uterus) . It is also being studied in the treatment of other conditions and types of cancer. Leuprolide acetate initially causes the pituitary gland to make more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), temporarily increasing testosterone levels in men and estrogen levels in women. With continued use, leuprolide acetate lowers the amount of LH and FSH the pituitary gland releases, leading to a drop in testosterone levels in men and estrogen levels in women. Leuprolide acetate may stop the growth of cancer cells that need testosterone to grow and stop the growth of endometrial tissue and uterine fibroids. It is a type of hormone therapy called a gonadotropin-releasing hormone (GnRH) agonist. Also called Eligard and Lupron Depot.

  2. The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.

Table 1. Record
IdentifierMLC-T-ONC-004801
FieldOncology and biomedicine
AbbreviationLEUP
SynonymsEligard; Lupron Depot; leuprorelin acetate
ReferencesNCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-004801",
  "term": "Leuprolide acetate",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used under the brand names Eligard and Lupron Depot to treat prostate cancer and under the brand name Lupron Depot to treat problems with the endometrium (lining of the uterus) and uterine fibroids (noncancerous growths of the uterus) . It is also being studied in the treatment of other conditions and types of cancer. Leuprolide acetate initially causes the pituitary gland to make more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), temporarily increasing testosterone levels in men and estrogen levels in women. With continued use, leuprolide acetate lowers the amount of LH and FSH the pituitary gland releases, leading to a drop in testosterone levels in men and estrogen levels in women. Leuprolide acetate may stop the growth of cancer cells that need testosterone to grow and stop the growth of endometrial tissue and uterine fibroids. It is a type of hormone therapy called a gonadotropin-releasing hormone (GnRH) agonist. Also called Eligard and Lupron Depot.",
    "The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression."
  ],
  "abbreviation": "LEUP",
  "synonyms": [
    "Eligard",
    "Lupron Depot",
    "leuprorelin acetate"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/leuprolide-acetate/"
}

Record 10,047 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.